Edesa Biotech

Yahoo Finance • 10 days ago

MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch

(RTTNews) - As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were am... Full story

Yahoo Finance • last month

Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment

Edesa Biotech Inc. (NASDAQ:EDSA) is one of the 10 Unstoppable Stocks That Could Double Your Money. Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollm... Full story

Yahoo Finance • 5 months ago

Edesa Biotech GAAP EPS of -$1.27 beats by $0.51

* Edesa Biotech press release [https://seekingalpha.com/pr/20338470-edesa-biotech-reports-fiscal-year-2025-results] (EDSA [https://seekingalpha.com/symbol/EDSA]): FY GAAP EPS of -$1.27 beats by $0.51. * At September 30, 2025, Edesa had... Full story

Yahoo Finance • 7 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consist... Full story

Yahoo Finance • 9 months ago

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment landscape is evolving with a shift tow... Full story

Yahoo Finance • 10 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story

Yahoo Finance • 10 months ago

Edesa Biotech files $150M mixed securities shelf offering

* Edesa Biotech (NASDAQ:EDSA [https://seekingalpha.com/symbol/EDSA]) has filed to offer up to $150M in a mix of securities. * The offering may include common shares, preferred shares, warrants, debt securities, subscription rights, and... Full story

Yahoo Finance • last year

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment... Full story

Yahoo Finance • last year

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story

Yahoo Finance • last year

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (... Full story